The Maintenance Treatment of Apatinib/Capecitabine Versus Observation in Advanced Gastric Cancer
A Phase III Study of Comparing the Maintenance Treatment of Apatinib, Capecitabine and Observation After First-line Therapy in Advanced Gastric Cancer
Sponsor: Fudan University
This PHASE3 trial investigates Apatinib and Capecitabine and is currently ongoing. Fudan University leads this study, which shows 5 recorded versions since 2019 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE3
Status: Unknown Status → Unknown
-
Apr 2024 — Jul 2024 [monthly]
Unknown Status PHASE3
Status: Not Yet Recruiting → Unknown Status
-
Jan 2021 — Apr 2024 [monthly]
Not Yet Recruiting PHASE3
-
Apr 2019 — Jan 2021 [monthly]
Not Yet Recruiting PHASE3
First recorded
Mar 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Fudan University
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.